Efficacy of intranasal fluticasone furoate for prevention chronic rhinosinusitis in nasopharyngeal carcinoma patient: A randomized controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210203001

Enrollment

Registered

2021-02-03

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post radiation chronic rhinosinusitis in nasopharyngeal carcinoma patients Rhinosinusitis Radiation

Interventions

Fluticasone 2 puff twice a day from the first day of radiotherapy until 6 months post radiation

Experimental Drug

Fluticasone furoate

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Nasopharyngeal carcinoma patients age > 18 years who just got the diagnosis and will start radiotherapy

Exclusion criteria

Exclusion criteria: 1. patients who has sinus surgery before 2. patients with rhinosinusitis infection in the past 6 months 3. patients who has been using intranasal corticosteroids before

Design outcomes

Primary

Measure	Time frame
Chronic rhinosinusitis 6 months after intervention Lund mackay score	—

Secondary

Measure	Time frame
Rhinosinusitis 6 months SNOT22 score	—

Countries

Thailand

Contacts

Public ContactNualwan Leelapatharaphan

Mahidol university

nualwanp@gmail.com0896998994

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026